FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1579 April 9, 2009 Number 15

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ciardiello, F.

EGFR Antagonists in Cancer Treatment . In Table 2 (page 1163), the information for gefitinib under Approved Uses should give the FDA approval date as May 2003. In the Clinical Efficacy of EGFR Antagonists in Human Cancers section, in the paragraph beginning "In a phase 2 study" (page 1164), the words "gefitinib or" should be deleted from the fourth and fifth sentences; only erlotinib should be named. In the next paragraph, beginning "On the basis" (page 1164), the words "or erlotinib" should be added to the third and fourth sentences after gefitinib; both gefitinib and erlotinib should be named. In the last paragraph of the section, in the penultimate sentence (page 1165), the word "binorelbine" should read "vinorelbine." In Table 3 (page 1166), the number of patients listed under Erlotinib should be 488; the median progression-free survival should read 1.8 for placebo and 2.2 for erlotinib, with a hazard ratio (and 95% confidence interval [CI]) of 0.61 (0.51–0.74), and the median overall survival should read 4.7 for placebo and 6.7 for erlotinib, with a hazard ratio (95% CI) of 0.70 (0.58–0.85). In Table 4 (page 1167), the median overall survival for the NCIC-CO.17 trial should read 4.6 under Best Supportive Care and 6.17 under Cetuximab. The article has been corrected at NEJM.org.

PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ciardiello, F.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.